These findings suggest that strategic upregulation or downregulation of specific miRNAs represents an effective approach to modulate Runx2, c-Myc, and cyclin D1 expression, potentially enabling novel therapeutic strategies against breast cancer bone metastasis. The gene discussed is MYC; the disease is breast carcinoma.